IL140094A0 - Vaccine - Google Patents

Vaccine

Info

Publication number
IL140094A0
IL140094A0 IL14009499A IL14009499A IL140094A0 IL 140094 A0 IL140094 A0 IL 140094A0 IL 14009499 A IL14009499 A IL 14009499A IL 14009499 A IL14009499 A IL 14009499A IL 140094 A0 IL140094 A0 IL 140094A0
Authority
IL
Israel
Prior art keywords
vaccine
Prior art date
Application number
IL14009499A
Other languages
English (en)
Original Assignee
Smithkline Beecham Biolog
Univ Ohio State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog, Univ Ohio State Res Found filed Critical Smithkline Beecham Biolog
Publication of IL140094A0 publication Critical patent/IL140094A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1242—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
IL14009499A 1998-06-11 1999-05-28 Vaccine IL140094A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9812613.9A GB9812613D0 (en) 1998-06-11 1998-06-11 Vaccine
PCT/US1999/011980 WO1999064067A2 (en) 1998-06-11 1999-05-28 Vaccine

Publications (1)

Publication Number Publication Date
IL140094A0 true IL140094A0 (en) 2002-02-10

Family

ID=10833591

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14009499A IL140094A0 (en) 1998-06-11 1999-05-28 Vaccine
IL140094A IL140094A (en) 1998-06-11 2000-12-05 Pimbrin P5-like peptide sequences and their uses

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL140094A IL140094A (en) 1998-06-11 2000-12-05 Pimbrin P5-like peptide sequences and their uses

Country Status (16)

Country Link
US (2) US20060257418A1 (xx)
EP (1) EP1083926A4 (xx)
JP (1) JP2002517218A (xx)
KR (1) KR20010052767A (xx)
CN (1) CN1201818C (xx)
AU (1) AU761293B2 (xx)
BR (1) BR9910973A (xx)
CA (1) CA2330238A1 (xx)
GB (1) GB9812613D0 (xx)
HU (1) HUP0302965A2 (xx)
IL (2) IL140094A0 (xx)
NO (1) NO20006191L (xx)
NZ (1) NZ508616A (xx)
PL (1) PL362988A1 (xx)
WO (1) WO1999064067A2 (xx)
ZA (1) ZA200007255B (xx)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
DE60032120T2 (de) 1999-03-19 2007-09-20 Glaxosmithkline Biologicals S.A. Impstoff gegen Streptococcus pneumoniae
GB0003502D0 (en) * 2000-02-15 2000-04-05 Smithkline Beecham Sa Vaccine
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0025493D0 (en) * 2000-10-17 2000-11-29 Smithkline Beecham Biolog Novel compounds
GB0102470D0 (en) * 2001-01-31 2001-03-14 Smithkline Beecham Biolog Novel compounds
KR100639397B1 (ko) * 2004-03-18 2006-10-26 (주)에스제이바이오메드 항비만용 면역원성 하이브리드 폴리펩타이드 및 이를포함하는 항비만 백신 조성물
EP1904519B1 (en) * 2005-07-08 2010-11-17 Nationwide Children's Hospital, Inc. Chimeric vaccine for haemophilus influenzae-induced disease
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
NZ569076A (en) 2005-12-22 2011-08-26 Glaxosmithkline Biolog Sa Vaccine comprising capsular polysaccharides conjugates from Streptococcus pneumoniae serotypes 19A and 19F
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
MY150105A (en) 2006-01-17 2013-11-29 Forsgren Arne A novel surface exposed haemophilus influenzae protein (protein e; pe)
DK2167121T3 (en) 2007-06-26 2015-11-23 Glaxosmithkline Biolog Sa A vaccine comprising Streptococcus pneumoniae kapselpolysaccharidkonjugater
KR20110111381A (ko) * 2009-01-07 2011-10-11 오츠카 세이야쿠 가부시키가이샤 전 인플루엔자균의 측정방법
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
CA2838188C (en) 2011-06-04 2017-04-18 Rochester General Hospital Research Institute Compositions and methods related to p6 of haemophilus influenzae
EP2964257A4 (en) 2013-03-08 2016-10-26 Res Inst Nationwide Childrens Hospital TRANSCUTANEOUS DOSE FORMULATION
CN103405760A (zh) * 2013-06-19 2013-11-27 中国科学院海洋研究所 迟缓爱德华氏菌菌毛蛋白FimA的应用
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
US20210162042A1 (en) 2017-05-30 2021-06-03 Glaxosmithkline Biologicals S.A. Novel methods for manufacturing an adjuvant
MX2020005481A (es) 2017-12-01 2020-12-07 Glaxosmithkline Biologicals Sa Purificacion de saponina.
CA3107077A1 (en) 2018-08-07 2020-02-13 Glaxosmithkline Biologicals Sa Processes and vaccines
US20220339282A1 (en) 2018-11-29 2022-10-27 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
WO2020245207A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0699076B1 (en) * 1993-05-18 2002-10-30 The Ohio State University Research Foundation Otitis media vaccine
US6248562B1 (en) * 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
US5770213A (en) * 1994-05-05 1998-06-23 American Cyanamid Company Purified nontypable haemophilus influenzae P5 protein as a vaccine for nontypable haemophilus influenzae infection
US5843464A (en) * 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
GB0003502D0 (en) * 2000-02-15 2000-04-05 Smithkline Beecham Sa Vaccine
EP1904519B1 (en) * 2005-07-08 2010-11-17 Nationwide Children's Hospital, Inc. Chimeric vaccine for haemophilus influenzae-induced disease

Also Published As

Publication number Publication date
US20060257418A1 (en) 2006-11-16
JP2002517218A (ja) 2002-06-18
BR9910973A (pt) 2001-09-18
KR20010052767A (ko) 2001-06-25
ZA200007255B (en) 2002-02-07
GB9812613D0 (en) 1998-08-12
CA2330238A1 (en) 1999-12-16
IL140094A (en) 2006-08-20
AU761293B2 (en) 2003-05-29
WO1999064067A9 (en) 2002-08-15
WO1999064067A2 (en) 1999-12-16
CN1306437A (zh) 2001-08-01
AU4102199A (en) 1999-12-30
NO20006191D0 (no) 2000-12-06
NO20006191L (no) 2001-02-07
EP1083926A1 (en) 2001-03-21
CN1201818C (zh) 2005-05-18
EP1083926A4 (en) 2006-01-18
US20090191234A1 (en) 2009-07-30
HUP0302965A2 (hu) 2003-12-29
PL362988A1 (en) 2004-11-15
NZ508616A (en) 2003-09-26

Similar Documents

Publication Publication Date Title
IL140094A0 (en) Vaccine
GB9712347D0 (en) Vaccine
GB9718901D0 (en) Vaccine
PL341761A1 (en) Vaccine
GB9711990D0 (en) Vaccine
GB9726555D0 (en) Vaccine
GB9720585D0 (en) Vaccine
PL343065A1 (en) Vaccine composition
HUP0105392A3 (en) Enhanced vaccines
GB9822714D0 (en) Vaccines
IL139467A0 (en) Vaccine
GB9801870D0 (en) Vaccine composition
GB9821821D0 (en) Schistomiasis vaccine
GB9820956D0 (en) Vaccine
GB9807805D0 (en) Vaccine
GB9811954D0 (en) Vaccine
GB9802543D0 (en) Vaccine
GB9812773D0 (en) Vaccine
GB9828035D0 (en) Vaccine
GB9822709D0 (en) Vaccine
GB9807933D0 (en) Vaccine
GB9812228D0 (en) Vaccine
GB9822703D0 (en) Vaccine
GB9805961D0 (en) Vaccine
GB9822712D0 (en) Vaccine

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed